TR199701048T1 - Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�. - Google Patents

Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�.

Info

Publication number
TR199701048T1
TR199701048T1 TR97/01048T TR9701048T TR199701048T1 TR 199701048 T1 TR199701048 T1 TR 199701048T1 TR 97/01048 T TR97/01048 T TR 97/01048T TR 9701048 T TR9701048 T TR 9701048T TR 199701048 T1 TR199701048 T1 TR 199701048T1
Authority
TR
Turkey
Prior art keywords
fumagilol
rlanmas
revlerinin
kullan
enfeksiyonlar
Prior art date
Application number
TR97/01048T
Other languages
English (en)
Turkish (tr)
Inventor
Molina Jean-Michel
Derouin Francis
Original Assignee
Sanofi
Assistance Publique-Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, Assistance Publique-Hopitaux De Paris filed Critical Sanofi
Publication of TR199701048T1 publication Critical patent/TR199701048T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR97/01048T 1995-03-27 1996-03-26 Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�. TR199701048T1 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
TR199701048T1 true TR199701048T1 (xx) 1998-01-21

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01048T TR199701048T1 (xx) 1995-03-27 1996-03-26 Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�.

Country Status (25)

Country Link
US (1) US5900431A (enExample)
EP (1) EP0817626B1 (enExample)
JP (1) JP3260378B2 (enExample)
KR (1) KR100286920B1 (enExample)
CN (1) CN1072485C (enExample)
AP (1) AP646A (enExample)
AT (1) ATE172641T1 (enExample)
AU (1) AU706161B2 (enExample)
CA (1) CA2216623C (enExample)
CZ (1) CZ286821B6 (enExample)
DE (1) DE69600879T2 (enExample)
DK (1) DK0817626T3 (enExample)
EA (1) EA000150B1 (enExample)
ES (1) ES2128846T3 (enExample)
FR (1) FR06C0014I2 (enExample)
HU (1) HU224028B1 (enExample)
IS (1) IS2048B (enExample)
NO (1) NO315968B1 (enExample)
NZ (1) NZ304906A (enExample)
OA (1) OA10515A (enExample)
PL (1) PL183378B1 (enExample)
SK (1) SK283883B6 (enExample)
TR (1) TR199701048T1 (enExample)
UA (1) UA41446C2 (enExample)
WO (1) WO1996030010A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO2000050084A1 (fr) * 1999-02-26 2000-08-31 Sanofi-Synthelabo Formulation stable contenant de la fumagilline
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CA2706914A1 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
EP2847176A1 (en) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
AU2013337287B2 (en) 2012-11-05 2017-03-23 Zafgen, Inc. Methods of treating liver diseases
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
CA2216623C (en) 2005-05-31
CA2216623A1 (en) 1996-10-03
PL322470A1 (en) 1998-02-02
CN1072485C (zh) 2001-10-10
ES2128846T3 (es) 1999-05-16
NZ304906A (en) 1999-06-29
EP0817626B1 (fr) 1998-10-28
HUP9801220A2 (hu) 1999-09-28
FR06C0014I2 (enExample) 2006-12-29
CN1179715A (zh) 1998-04-22
JP3260378B2 (ja) 2002-02-25
PL183378B1 (pl) 2002-06-28
ATE172641T1 (de) 1998-11-15
NO974466D0 (no) 1997-09-26
AU5278696A (en) 1996-10-16
AP646A (en) 1998-04-27
EP0817626A2 (fr) 1998-01-14
IS4557A (is) 1997-09-11
EA000150B1 (ru) 1998-10-29
US5900431A (en) 1999-05-04
AU706161B2 (en) 1999-06-10
CZ286821B6 (en) 2000-07-12
DK0817626T3 (da) 1999-07-12
EA199700267A1 (ru) 1998-04-30
FR06C0014I1 (enExample) 2006-11-17
JPH11506421A (ja) 1999-06-08
AP9701092A0 (en) 1997-10-31
KR100286920B1 (ko) 2001-04-16
MX9707150A (es) 1998-07-31
NO974466L (no) 1997-09-26
KR19980703271A (ko) 1998-10-15
UA41446C2 (uk) 2001-09-17
DE69600879D1 (de) 1998-12-03
IS2048B (is) 2005-09-15
HUP9801220A3 (en) 2001-10-29
DE69600879T2 (de) 1999-06-02
SK130797A3 (en) 1998-03-04
SK283883B6 (sk) 2004-04-06
CZ304997A3 (en) 1997-12-17
OA10515A (fr) 2002-04-24
HU224028B1 (hu) 2005-05-30
WO1996030010A3 (fr) 1996-11-28
NO315968B1 (no) 2003-11-24
WO1996030010A2 (fr) 1996-10-03

Similar Documents

Publication Publication Date Title
TR199701048T1 (xx) Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�.
BR8802237A (pt) Sistema gerador de arco e sistema gerador de gas ionizado
AR038429A2 (es) Compuestos 15-alquil-16-hidroxilo de marcfortina
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
EE9800070A (et) Vehiikulitena kasutatavad mikroemulsioonid toimivate ühendite manustamiseks
MX9205725A (es) Formulaciones generantes de gas no azidico
FI955315L (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
EP0676954A4 (en) HIV LOCK VIRUS.
FI942112L (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
DE69002720D1 (de) Zuendverstaerkeranlage bei gasfackel.
NL193665B (nl) Zuurstofgenererende elektrode.
ATE74804T1 (de) Verringerung des durchmessers von rohrfoermigen koerpern.
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
ES2138247T3 (es) Composicion y uso.
GR1000318B (el) Θεραπευτικως δραστικη υποκατεστημενη βενζιμιδαζολη και μεθοδος για την παρασκευη αυτης.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ES556864A0 (es) Procedimiento para la obtencion de benzopiranos sustituidos.
TR199801196T2 (xx) Biyolojik aktif benzotiyazolon etanaminler.
IT8322485A0 (it) Procedimento e dispositivo perl'azionamento e la sincronizzazione di rulli.
AU7636894A (en) Substituted tetronic acids useful for treating hiv and other retroviruses
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.
ITMI911944A1 (it) Quadro dei licci
ES2014004B3 (es) Dispositivo para la ionizacion de oxigeno gaseoso.
DK0817786T3 (da) Substituerede tetronsyrer, der er nyttige til behandling af HIV og andre retrovira